Self-Selection Studies Need Room To Evaluate Purchase Decisions – Expert
This article was originally published in The Tan Sheet
Executive Summary
FDA should allow researchers more flexibility to evaluate consumers’ purchase decisions in self-selection studies for OTC drugs, according to contract research organization PEGUS Research.
You may also be interested in...
Naloxone OTC Switch NDA Has US FDA Concerned Labeling Will Cause User Error, Delay Delivery
CDER will ask advisory panel “whether additional labeling information might mitigate risk of use errors” for Emergent’s naloxone nasal spray made available OTC and whether results of firm’s human factors study “support that consumers are able to correctly administer nonprescription [naloxone nasal spray] in an emergency situation.”
Statin Label Change Stirs OTC Switch Discussions
FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.
Statin Label Change Stirs OTC Switch Discussions
FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.